玻璃体腔注射阿柏西普联合全视网膜光凝治疗糖尿病视网膜病变增殖期黄斑水肿的疗效分析

doi:10.3969/j.issn.1007-3205.2022.02.012

河北医科大学学报 ›› 2022, Vol. 43 ›› Issue (2): 183-186,197.doi: 10.3969/j.issn.1007-3205.2022.02.012

玻璃体腔注射阿柏西普联合全视网膜光凝治疗糖尿病视网膜病变增殖期黄斑水肿的疗效分析

广东省深圳市南山区蛇口人民医院眼科，广东深圳 518067

出版日期:2022-02-25 发布日期:2022-03-03
作者简介:李爽（1981-），女，河南唐河人，广东省深圳市南山区蛇口人民医院主治医师，医学硕士，从事眼科疾病诊治研究。
基金资助:
深圳市南山区技术研发和创意设计项目分项资金教育（卫生）科技资助项目（南科研卫2018041号）

Efficacy of intravitreal injection of aflibercept combined with pan-retinal photocoagulation in the treatment of diabetic macular edema induced by proliferative diabetic retinopathy

Department of Ophthalmology, Shekou People′s Hospital of Nanshan District, Guangdong Province，Shenzhen 518067， China

Online:2022-02-25 Published:2022-03-03

摘要/Abstract

摘要： 目的研究玻璃体腔注射阿柏西普联合全视网膜光凝术（pan-retinal photocoagulation，PRP）治疗增殖期糖尿病视网膜病变（proliferative diabetic retinopathy，PDR）所致糖尿病性黄斑水肿（diabetic macular edema，DME）的效果。
方法纳入具有DME的PDR患者60例（60眼），随机分为对照组和试验组，前者接受单纯PRP治疗，后者接受玻璃体腔注射阿柏西普联合PRP治疗。治疗1个月后，比较2组最佳矫正视力（best corrected visual acuity，BCVA）、中央黄斑厚度（entral macular thickness，CMT）、眼内压和并发症发生率。
结果治疗前，2组BCVA、眼内压和CMT比较差异无统计学意义（P＞0.05）。治疗后，试验组BCVA优于对照组，眼内压、CMT低于对照组（P＜0.05）。与治疗前相比，2组BCVA均提高，CMT均降低，对照组的眼内压较治疗前有所升高（P＜0.05）。试验组的新生血管和无灌注区消退率均优于对照组，试验组的并发症发生率低于对照组（P＜0.05）。
结论阿柏西普联合PRP相比于单纯PRP治疗DR增殖期的DME，能够更有效地消退黄斑水肿，更好地提升视力，并能减少并发症的发生率，因此这种联合治疗是一种值得推广的治疗方法。

关键词: 糖尿病视网膜病变 , 阿柏西普, 全视网膜光凝术

Abstract: Objective To study the effect of intravitreal injection of aflibercept combined with pan-retinal photocoagulation(PRP) in the treatment of diabetic macular edema(DME) induced by proliferative diabetic retinopathy(PDR).
Methods Sixty patients(60 eyes) with PDR and DME were randomly divided into control group and experimental group. The former was treated with PRP alone, and the latter was treated with intravitreal injection of arbasip combined with PRP. At one month after treatment, the best corrected visual acuity(BCVA), central macular thickness(CMT), intraocular pressure and the incidence of complications were compared between two groups.
Results Before treatment, there was no significant difference in BCVA, intraocular pressure and CMT between two groups(P＞0.05). After treatment, BCVA in the experimental group was better than that in the control group, while intraocular pressure and CMT were lower than those in the control group(P＜0.05). Compared with those before treatment, BCVA increased while CMT decreased in both groups, and intraocular pressure increased in the control group(P＜0.05). The regression rates of neovascularization and non-perfusion area in the experimental group were better than those in the control group, and the incidence of complications in the experimental group was lower than that in the control group(P＜0.05).
Conclusion Compared with PRP alone in the treatment of DME in the proliferative stage of DR, aflibercept combined with PRP can more effectively eliminate macular edema, better improve vision, and reduce the incidence of complications. Therefore, this combined treatment is a treatment method worthy of popularization.

Key words: diabetic retinopathy, aflibercept, , pan-retinal photocoagulation

李爽, 张海召, 姜晓丹, 蒋燕铌. 玻璃体腔注射阿柏西普联合全视网膜光凝治疗糖尿病视网膜病变增殖期黄斑水肿的疗效分析[J]. 河北医科大学学报, 2022, 43(2): 183-186,197.

LI Shuang, ZHANG Hai-zhao, JIANG Xiao-dan, JIANG Yan-ni. Efficacy of intravitreal injection of aflibercept combined with pan-retinal photocoagulation in the treatment of diabetic macular edema induced by proliferative diabetic retinopathy[J]. Journal of Hebei Medical University, 2022, 43(2): 183-186,197.

[1]	李雪景, 陈冬梅, 段佳良, 姚一民, 尚庆丽. 联合手术治疗增殖性糖尿病视网膜病变的继发性闭角型新生血管性青光眼的临床效果观察 [J]. 河北医科大学学报, 2023, 44(3): 319-323.
[2]	吴苏敏, 周欣, 王丽波. 血清CMKLR1、FSTL1水平与糖尿病视网膜病变严重程度相关性 [J]. 河北医科大学学报, 2023, 44(2): 189-193,213.
[3]	王艳新, 贾冠美, 曹朗, 曹顺义, 张士宏. 血浆miR-let-7e-5p、LncRNA NEAT1表达水平与2型糖尿病视网膜病变的关系 [J]. 河北医科大学学报, 2022, 43(10): 1167-1171.
[4]	白洁, 宋妮娟. 基于聚焦解决模式的强化护理对糖尿病性视网膜病变患者负性情绪、依从性及视功能的影响[J]. 河北医科大学学报, 2021, 42(11): 1298-1301,1306.
[5]	刘慧（综述）, 刘丹岩（审校）. 增殖性糖尿病视网膜病变玻璃体切除术后发生新生血管性青光眼的影响因素[J]. 河北医科大学学报, 2021, 42(11): 1357-1361.
[6]	窦方方, 李振通, 曹素平, 邓志峰. 原花青素调控miR-21表达对糖尿病视网膜病变大鼠血管内皮细胞功能及视网膜神经节细胞的保护机制研究[J]. 河北医科大学学报, 2020, 41(12): 1379-1383,1388.
[7]	陈伽俐，李〓炜，李〓林*. 雷珠单抗联合577 nm激光光凝治疗重度非增生型糖尿病视网膜病变伴黄斑水肿的效果观察[J]. 河北医科大学学报, 2019, 40(7): 834-837.
[8]	刘〓影，王红霞，周娜磊，段佳良，杨〓欣，安建斌*. 预警机制人性化护理在PDR玻璃体切除患者中的应用观察[J]. 河北医科大学学报, 2018, 38(6): 688-690,694.
[9]	董白霞1，王家瑶2，包永琴1，王振东1. EPA治疗后对糖尿病性视网膜病变大鼠视网膜组织VEGF、flk1、bax、bcl2表达的影响[J]. 河北医科大学学报, 2018, 38(3): 313-317,321.
[10]	王霖霞，苏〓娜，张云娜，郭宁宁，王光亚. 25羟维生素D3、hsCRP与糖尿病视网膜病变相关性研究[J]. 河北医科大学学报, 2018, 38(10): 1149-1152,1184.
[11]	刘俊辉1,李春江1,李玉涛1,2*. 黄芪多糖对糖尿病大鼠视网膜病变的保护作用[J]. 河北医科大学学报, 2017, 37(7): 797-800.
[12]	刘俊辉1,2,李春江2,李玉涛2,3*. 白藜芦醇对糖尿病大鼠视网膜病变的影响#br#[J]. 河北医科大学学报, 2017, 37(11): 1310-1314.
[13]	董白霞，包永琴，王振东，王家瑶. VEGF、flk1、bax、 bcl2在不同类型DR大鼠模型视网膜组织中表达变化的观察[J]. 河北医科大学学报, 2016, 37(11): 1289-1293.
[14]	李亚永;薛鹏;王瑜玲;刘岩;李玉坤;江新利. 血浆色素上皮衍生因子及血管内皮生长因子含量与2型糖尿病视网膜病变相关性的研究[J]. , 2015, 36(6): 628-628.
[15]	肖雪娜;王心捷. 糖尿病患者血清CA199水平升高与糖化血红蛋白及糖尿病视网膜病变的关系[J]. , 2015, 36(6): 695-695.

玻璃体腔注射阿柏西普联合全视网膜光凝治疗糖尿病视网膜病变增殖期黄斑水肿的疗效分析

Efficacy of intravitreal injection of aflibercept combined with pan-retinal photocoagulation in the treatment of diabetic macular edema induced by proliferative diabetic retinopathy

HTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价